Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $422,148.36 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the transaction, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Alnylam Pharmaceuticals Stock Up 0.2 %

Shares of ALNY traded up $0.39 on Wednesday, hitting $253.74. 718,060 shares of the stock traded hands, compared to its average volume of 877,936. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a market capitalization of $32.73 billion, a PE ratio of -96.70 and a beta of 0.39. The business has a 50 day simple moving average of $272.32 and a 200 day simple moving average of $240.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same period in the previous year, the business posted $1.15 earnings per share. The company’s revenue for the quarter was down 33.3% compared to the same quarter last year. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ALNY. Ashton Thomas Private Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $26,000. Huntington National Bank lifted its stake in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares in the last quarter. Hollencrest Capital Management purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. Washington Trust Advisors Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $42,000. Finally, True Wealth Design LLC lifted its stake in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. JPMorgan Chase & Co. upped their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. Scotiabank upped their target price on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Finally, Piper Sandler reissued an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.